FluoAB
PreclinicalSmall molecule
FluoAB is one of 13 small molecule programs targeting Tumor. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
13 competitors in Tumor
#DrugCompanyPhaseTrials
1Opdivo
Bristol-Myers SquibbPhase 2
Gemzar
Johnson & JohnsonPhase 2
Tuoyi
CCoherus Oncology, Inc.
Phase 2
Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Phase 2
Giapreza
LLa Jolla Pharmaceutical Company
Phase 2
Apatinib
LLaNova Medicines Zhejiang Co., Ltd.
Phase 2
LM-302
LLaNova Medicines Zhejiang Co., Ltd.
Phase 2
MRI Contrast-Enhancing Agents
SanofiPhase 1
HP518 - Dose Expansion
HHinova Pharmaceuticals Aus Pty Ltd
Phase 2
ASK120067
JJiangsu Aosaikang Pharmaceutical Co., Ltd.
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for FluoAB. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- CChinese Academy of Sciences